The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial).

@article{Phoa2017TheCO,
  title={The cost-effectiveness of radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: results from a randomized controlled trial (SURF trial).},
  author={K Nadine Phoa and Wilda D. Rosmolen and Bas L. A. M. Weusten and Raf Bisschops and Erik J. Schoon and Shefali Das and Krish Ragunath and Grant M. Fullarton and Massimiliano DiPietro and Narayanasamy Ravi and Jan G. P. Tijssen and Marcel G. W. Dijkgraaf and Jacques J. Bergman},
  journal={Gastrointestinal endoscopy},
  year={2017},
  volume={86 1},
  pages={
          120-129.e2
        }
}
BACKGROUND AND AIMS The Surveillance versus Radiofrequency Ablation (SURF) trial randomized 136 patients with Barrett's esophagus (BE) containing low-grade dysplasia (LGD), to receive radiofrequency ablation (ablation, n = 68) or endoscopic surveillance (control, n = 68). Ablation reduced the risk of neoplastic progression to high-grade dysplasia and esophageal adenocarcinoma (EAC) by 25% over 3 years (1.5% for ablation vs 26.5% for control). We performed a cost-effectiveness analysis from a… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

From This Paper

Figures and tables from this paper.

References

Publications referenced by this paper.
Showing 1-10 of 21 references

The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus

Gastroenterology • 2012
View 4 Excerpts
Highly Influenced

The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends.

Annals of oncology : official journal of the European Society for Medical Oncology • 2012
View 1 Excerpt